Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2

by Na Luo, Luigi Formisano, Paula I. Gonzalez-Ericsson, Violeta Sanchez, Phillip T. Dean, Susan R. Opalenik, Melinda E. Sanders, Rebecca S. Cook, Carlos L. Arteaga, Douglas B. Johnson, Justin M. Balko
Published 2018-06-01